Evaluation of lipoprotein(a) electrophoretic and immunoassay methods in discriminating risk of calcific aortic valve disease and incident coronary heart disease: The multi-ethnic study of atherosclerosis

Jing Cao, Brian T. Steffen, Weihua Guan, Matthew Budoff, Erin D. Michos, Jorge R. Kizer, Wendy S. Post, Michael Y. Tsai

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

BACKGROUND: A number of lipoprotein(a) [Lp(a)] analytical techniques are available that quantify distinct particle components, yet their clinical efficacy has not been comprehensively evaluated. This study determined whether Lp(a) mass [Lp(a)-M], Lp(a) cholesterol content [Lp(a)-C], and particle concentration [Lp(a)-P] differentially discriminated risk of calcific aortic valve disease(CAVD) or incident coronary heart disease (CHD) among 4679 participants of the Multi-Ethnic Study of Atherosclerosis (MESA).METHODS: Lp(a)-M, Lp(a)-C, and Lp(a)-P were measured in individuals without clinical evidence of CHD at baseline. Relative risk regression and Cox proportional analysis determined associations between Lp(a) and the presence of CAVD or 12-year risk of CHD, respectively. To control for the relatively high lower limits of quantification for Lp(a)-C and Lp(a)-P assays, the upper 25th and 15th percentiles were selected as analytical cutoff points.RESULTS: Regardless of method or analytical cutoff, high Lp(a) concentrations were significantly associated with CAVD and CHD in MESA participants following adjustment for typical cardiovascular risk factors. Stratifying by race/ethnicity rendered most associations nonsignificant after correction for multiple comparisons, but Lp(a) remained associated with CAVD in whites irrespective of method (all P< 0.0001).CONCLUSIONS: Associations of Lp(a)-C, Lp(a)-P, and Lp(a)-M with CAVD or incident CHD were similar in this entire MESA sample using a dichotomized statistical approach. However, the high lower limits of quantification and imprecision of the Lp(a)-C and Lp(a)-P assays limited their usefulness in our analyses and would likely do so in research and clinical settings.

Original languageEnglish (US)
Pages (from-to)1705-1713
Number of pages9
JournalClinical Chemistry
Volume63
Issue number11
DOIs
StatePublished - Nov 2017

Bibliographical note

Funding Information:
Employment or Leadership: None declared. Consultant or Advisory Role: None declared. Stock Ownership: J.R. Kizer, Gilead Sciences, Inc., Pfizer, Inc. Honoraria: None declared. Research Funding: Contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute and by grants UL1-TR-000040 and UL1-TR-001079 from NCRR. Expert Testimony: J.R. Kizer, Cooney, Sculley, and Dowling. Patents: None declared.

PubMed: MeSH publication types

  • Journal Article
  • Randomized Controlled Trial

Fingerprint Dive into the research topics of 'Evaluation of lipoprotein(a) electrophoretic and immunoassay methods in discriminating risk of calcific aortic valve disease and incident coronary heart disease: The multi-ethnic study of atherosclerosis'. Together they form a unique fingerprint.

Cite this